We recently published a list of the 10 Best Performing Healthcare Stocks So Far in 2025. In this article, we are going to ...

After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $40.0 and $60.0 for SpringWorks Therapeutics, spanning the last ...

Guggenheim lowered the firm’s price target on SpringWorks Therapeutics (SWTX) to $77 from $78 and keeps a Buy rating on the shares. The firm is ...

SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.44 per share a year ago. These ...

SPRINGWORKS THERAPEUTICS ($SWTX) posted quarterly earnings results on Thursday, February 20th. The company reported earnings of -$1.04 per share, missing estimates of ...

Achieved $61.5 million and $172.0 million in fourth quarter and full year 2024 OGSIVEO® (nirogacestat) U.S. net product ...

SWTX reports mixed fourth-quarter 2024 results. Its newly approved desmoid tumor drug, Ogsiveo, witnesses a strong launch.

Shares of SWTX stock opened at $56.30 on Wednesday. SpringWorks Therapeutics has a 52 week low of $28.21 and a 52 week high of $60.00. The stock has a market capitalization of $4.19 billion ...

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Aura Biosciences Inc (AURA – Research Report) ...

In this article, we are going to take a look at where SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) stands against other best performing healthcare stocks so far in 2025. Despite the ongoing craze ...

SpringWorks Therapeutics (SWTX) came out with a quarterly loss of $1.04 per share versus the Zacks Consensus Estimate of a loss of $0.72. This compares to loss of $1.44 per share a year ago.